International Workshop on HIV & Hepatitis Co-infection 2017

Hepatitis E in HIV- Kenneth Sherman, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

News on hepatitis delta and HIV infections- Vincent Soriano, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Management of HCV in intravenous drug users: special considerations- Rui Sarmento e Castro, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Pro stance- Francesca Ceccherini– Silberstein, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Special considerations before / during / after DAA therapy- Kosh Agarwal, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Virologist's perspective - Charles Boucher, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Con stance (Not available)- Mark Nelson, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Pharmacologist's perspective- David Back, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Are there any special populations in treatment of HCV left?- Douglas Dieterich, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?- R. Valente

Slideset

HIV

Viral Hepatitis and Liver Disease

HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. Seixas

Slideset

HIV

Viral Hepatitis and Liver Disease

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1- P. Buggish

Slideset

HIV

Viral Hepatitis and Liver Disease

Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)- P. Rodriguez Cortes

Slideset

HIV

Viral Hepatitis and Liver Disease

Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unravelled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort - L. Cuypers

Slideset

HIV

Viral Hepatitis and Liver Disease

Acute hepatitis A outbreak among men who have sex with men in Milan: the role of HIV co-infection- M. Merli

Slideset

HIV

Viral Hepatitis and Liver Disease

Outbreak of hepatitis A in men who have sex with men in 2017 - Experience in an infectious diseases department, Hospital de Curry Cabral - CHLC, Lisbon, Portugal- A.R. Garrote

Slideset

HIV

Viral Hepatitis and Liver Disease

Direct acting antiviral treatment for HCV in safety net settings: Provider and HIV/HCV co-infected patient preferences- M. Peters

Slideset

HIV

Viral Hepatitis and Liver Disease

Non liver and survival benefits of SVR in HCV - Marion Peters, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

The use of HIV+ or HCV+ organs in transplantation- Stefano Fagiuoli, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Case based debate: Is HCC increased with DAA therapy? Con stance- Nicolás Merchante, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Case based debate: Is HCC increased with DAA therapy? Pro stance- Douglas Dieterich, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Antifibrotics and fatty liver drugs in the pipeline- Sanjay Bhagani, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in HCV/HIV coinfected patients- J. Méndez

Slideset

HIV

Viral Hepatitis and Liver Disease

Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro

Slideset

HIV

Viral Hepatitis and Liver Disease

Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia- E. Dolmazashvili

Slideset

HIV

Viral Hepatitis and Liver Disease

HCV elimination program in Georgia: Successes and challenges- Nikoloz Chkhartishvili, MD, MS, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

What challenges remain in viral hepatitis- Jürgen Rockstroh, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

International Workshop on HIV & Hepatitis Co-infection 2017

Hepatitis E in HIV- Kenneth Sherman, MD, PhD

News on hepatitis delta and HIV infections- Vincent Soriano, MD, PhD

Management of HCV in intravenous drug users: special considerations- Rui Sarmento e Castro, MD, PhD

EASL highlights 2017- Jürgen Rockstroh, MD

Management of end-stage liver disease in HIV patients- Ana Morbey, MD

New insights in management of HIV/HBV co-infected patients- Juan Berenguer, MD

HBV cure: what is coming in 5 – 10 years?- Patrick Kennedy, MD

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Pro stance- Francesca Ceccherini– Silberstein, PhD

Special considerations before / during / after DAA therapy- Kosh Agarwal, MD

Virologist's perspective - Charles Boucher, MD, PhD

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Con stance (Not available)- Mark Nelson, MD

Pharmacologist's perspective- David Back, PhD

Are there any special populations in treatment of HCV left?- Douglas Dieterich, MD

HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?- R. Valente

HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. Seixas

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1- P. Buggish

Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)- P. Rodriguez Cortes

Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unravelled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort - L. Cuypers

Acute hepatitis A outbreak among men who have sex with men in Milan: the role of HIV co-infection- M. Merli

Outbreak of hepatitis A in men who have sex with men in 2017 - Experience in an infectious diseases department, Hospital de Curry Cabral - CHLC, Lisbon, Portugal- A.R. Garrote

Direct acting antiviral treatment for HCV in safety net settings: Provider and HIV/HCV co-infected patient preferences- M. Peters

Non liver and survival benefits of SVR in HCV - Marion Peters, MD

The use of HIV+ or HCV+ organs in transplantation- Stefano Fagiuoli, MD

Case based debate: Is HCC increased with DAA therapy? Con stance- Nicolás Merchante, MD

Case based debate: Is HCC increased with DAA therapy? Pro stance- Douglas Dieterich, MD

Antifibrotics and fatty liver drugs in the pipeline- Sanjay Bhagani, MD

Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in HCV/HIV coinfected patients- J. Méndez

Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro

Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia- E. Dolmazashvili

HCV elimination program in Georgia: Successes and challenges- Nikoloz Chkhartishvili, MD, MS, PhD

What challenges remain in viral hepatitis- Jürgen Rockstroh, MD

NASH and NAFLD in HIV: same or different? - Mariana Machado, MD